TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Jesus Prieto VALTUENA, et al Group No.: 1614 Serial No.: 09/674,445

Filed: November 1, 2000

Examiner.: Jegatheesan Seharaseyon

UTILIZATION OF INTERFERON ALPHA 5 IN THE TREATMENT OF For:

VIRAL HEPATOPATHIES

Attorney Docket No.: U 013039-2

Commissioner for Patents Washington, D.C. 20231

AMENDMENT

In response to the Official Action of June 3, 2003, please amend the application as follows:

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby-certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for \boxtimes Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. 1.10*

37 C.F.R. 1.8(a) Iail Post Office-to Address" \boxtimes with sufficient postage as first class mail. TRANSMISSION transmitted by facsimile to the Patent and Trademark Office. Signature Date: October 21, 2003 **CLIFFORD J. MASS** (type or print name of person certifying)

*WARNING:

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).

"Since the filing of correspondence under \S 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed.

Reg. 56,439, at 56,442.

10/28/2003 BSAYASI1 00000101 09674445

01 FC:2252

210.00 OP